Skip to main content
Fig. 4 | Pediatric Rheumatology

Fig. 4

From: Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China

Fig. 4

Laboratory characteristics in CAPS patients before and after canakinumab therapy. M0: before canakinumab treatment; Mmax: at the last follow-up time after canakinumab therapy. WBC: white blood cell; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SAA: serum amyloid A. ns: no significant; ** p < 0.01; *** p < 0.001; **** p < 0.0001; the boxes and whiskers indicate mean with SD

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096